EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO)

Aditya K Gupta iD, Mesbah Talukder, Elizabeth A Cooper iD, Lee Magal, Avner Shemer

Pathogens · 2025

DOI: 10.3390/pathogens14101049 ↗

At a glance

Journal article in Pathogens, 2025. Written by Aditya K Gupta and 4 co-authors. Institution: Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Major MEDLINE topics: Onychomycosis, Voriconazole, Antifungal Agents. 16 references. The full text is freely available (open access, CC BY 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

This retrospective case series evaluated off-label voriconazole for distal lateral subungual onychomycosis (DLSO) unresponsive to standard therapy. Twenty-nine culture-confirmed patients who had failed terbinafine (250 mg daily × 12 weeks) and itraconazole pulses (200 mg twice daily for 1 week/month × 3) received voriconazole (200 mg twice on day 1, then 200 mg daily for 3–4 months). Assessments occurred at 2, 4, 6–9, and 12 months; the primary endpoint was combined clinical cure (≥90% nail clearance) plus mycological cure (negative KOH and culture) at 12 months. Intention-to-treat included 29 patients; per-protocol included 27 (two did not complete follow-up). In the per-protocol cohort, combined cure was 55.6% (15/27) and mycological cure 74.1% (20/27). Complete clinical cure occurred in 66.7% (18/27); 25.9% (7/27) improved markedly, 3.7% (1/27) mildly, and 3.7% (1/27) showed no improvement. Voriconazole was well tolerated and may be considered for DLSO refractory to terbinafine ± itraconazole. Antifungal stewardship remains essential.

Subjects

MeSH terms (MEDLINE)

OnychomycosisVoriconazoleAntifungal AgentsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedTreatment OutcomeTerbinafineYoung Adult

Author keywords

clinical curedistal lateral subungual onychomycosis (DLSO)mycological curerefractory onychomycosisterbinafine failurevoriconazole

Substances

VoriconazoleAntifungal AgentsTerbinafine

Authors and institutions

  • Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • School of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
  • Department of Physiology and Pharmacology, University of Western Ontario, London, ON N6A 5C1, Canada.
  • Shemer Clinic, Netanya 4250602, Israel.
  • Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

ORCID profiles: Aditya K Gupta, Elizabeth A Cooper

Cite

APA

Gupta, A. K., Talukder, M., Cooper, E. A., Magal, L., & Shemer, A. (2025). Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO). Pathogens. https://doi.org/10.3390/pathogens14101049

Vancouver

Gupta AK, Talukder M, Cooper EA, Magal L, Shemer A. Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO). Pathogens. 2025. doi:10.3390/pathogens14101049

BibTeX
@article{Gupta2025,
  author = {Gupta, Aditya K and Talukder, Mesbah and Cooper, Elizabeth A and Magal, Lee and Shemer, Avner},
  title = {Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO)},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14101049}
}
Start for free →